Physician profile
Simon Iroha
NPI 1194973503
$1,532.03
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.98 · 2020: $59.36 · 2021: $234 · 2022: $437 · 2023: $474 · 2024: $316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $789.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $789.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $392.85 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $345.23 | 2020-2024 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $232.20 | 2020-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $200.43 | 2021-2023 | Brilinta |
| Lexicon Pharmaceuticals, INC. | $65.20 | 2023 | Inpefa |
| Abbvie INC. | $61.99 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $56.02 | 2023 | Verquvo, Dificid, Zerbaxa |
| Alnylam Pharmaceuticals INC. | $23.92 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $23.74 | 2024 | Lifevest |
| Pfizer INC. | $22.59 | 2021 | |
| Eisai INC. | $21.77 | 2022 | |
| Gilead Sciences, INC. | $20.46 | 2022 | |
| Aimmune Therapeutics, INC. | $20.27 | 2023 | |
| Baxter Healthcare | $15.66 | 2023 | Hillrom - Life 2000 Ventilation System |
| Novo Nordisk INC | $14.91 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.79 | 2023 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simon Iroha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.